Other substances

Clioquinol

A hydroxyquinoline antimicrobial.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Clioquinol is a copper-binding 8-hydroxyquinoline proteasomal inhibitor. It displays bacteriostatic, antifungal, and antiparasitic activities. It has potential antitumor properties, as well. Clioquinol is also used in veterinary medicine and is mostly applied topically (DrugBank, NCIt).

Clioquinol on PubChem
Clioquinol on Wikipedia


Synonyms

5-chloro-7-iodo-8-quinolinol

Marketed as

VIOFORM (marketing discontinued)

 

Structure image - Clioquinol

C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1

Supporting references

Link Tested on Impact factor Notes Publication date
Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro
Spike protein ACE2 Enzyme assay In vitro 		in vitro binding assay; in vitro enzyme assay; Vero E6 cells; SARS-CoV-2 strain USA_WA1/2020

The compound inhibited SARS-CoV-2-induced cytopathic effect in Vero E6 cells with an IC50 of 12.62 μM. It was shown to block the interaction between Spike protein RBD and a recombinant form of human ACE2 receptor. It also impeded ACE2’s exopeptidase activity in vitro.

 Mar/11/2021

AI-suggested references

Link Publication date
Inhibitory mechanism of clioquinol and its derivatives at the exopeptidase site of human angiotensin-converting enzyme-2 and receptor binding domain of SARS-CoV-2 viral spike.
Oct/30/2021
Export (.csv)